Mitochon Pharmaceuticals Mitochon Pharmaceuticals
  • Company
  • Science & Technology
  • Pipeline
  • News & Publications
  • Contact

Mitochon Pipeline

Compounds

MP101

Huntington’s Disease

Duchenne Muscular Dystrophy

Optic Neuritis

MP201

Multiple Sclerosis

Parkinson’s Disease

Pre-Clinical Efficacy

IND Enabling Activities

Phase I

Phase II

  • No Widgets

    "Secondary" needs some widgets.

  • Mitochon Pharmaceuticals Mitochon Pharmaceuticals
    • MP 201:
    • Parkinson’s Disease

    Parkinson’s Disease

    • The Sirt3 KO mouse model, exhibits increased vulnerability of striatal and hippocampal neurons to degeneration.
    • 6-OHDA in PBS injected into the right striatum of Sirt3 KO under stereotaxic guidance, the dopaminergic neurons are destroyed.
    • Prior to rotarod behavioral testing, MP101 was provided orally once per day for 14-days.

    OUR DATA SHOWS:
    MP101 Preserves Dopaminergic Neurons (TH+).
    MP101 has a striking effect on behavior on the rotarod.

    MP101 Preserves Dopaminergic Neurons (TH+).

    6-OHDA model has selectively kill dopaminergic SN neurons slowly over the two weeks post-injection (ipsilateral side). The day after the injection the mice begin a two week treatment with MP101 at 1 and 5mpk, but the SN neurons are protected from eminent cell death (TH positive).

    MP101 has a striking effect on behavior on the rotarod.

    MP101 treated mice stay on the rotarod 4x longer than placebo.
    Rotarod Test after 14-Days of Chronic Treatment with MP101 Showing Neuroprotection Against 6-OHDA-induced Degeneration of the Dopaminergic Neurons in the Nigrostriatal Pathway of Sirt3 KO mice.
    Mitochon Pharmaceuticals, Inc.
    970 Cross Lane
    Blue Bell, PA 19422
    © 2021 Mitochon Pharmaceuticals, All Rights Reserved
    Website designed and managed by WP Cinch
    PageLines